CHICAGO (EGMN) - The success of new combinations of novel agents in clinical trials has some experts wondering whether stem cell transplantation will still be necessary as frontline treatment for multiple myeloma.Updated results from the first randomized phase III trial to address this question did not show significant differences in outcomes between groups of young patients assigned to transplantation or to a novel combination, investigators reported at the annual meeting of the American Society...